Psychedelics for Emotional Numbness

(OAD1 Trial)

This trial aims to explore how two different drugs, Psilocybin and Dextromethorphan (a common cough suppressant), affect brain activity and emotional numbness in older adults with low well-being. Researchers seek to determine if these drugs can alter brain patterns and reduce inflammation markers in the body. Participants will receive varying doses of the drugs to compare their effects. Individuals over the age of 50 who have felt emotionally flat or disengaged might be suitable for this study. As a Phase 1 trial, this research focuses on understanding how these treatments work in people, offering participants the opportunity to be among the first to receive these innovative therapies.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the study team or your doctor to get a clear answer.

Studies have shown that psilocybin, when used in a controlled setting, can lead to strong emotional experiences. People often report feeling more connected and open. While most handle it well, risks exist. Some users have experienced temporary anxiety or confusion, especially with higher doses. Research suggests these effects usually don't last long.

Researchers are also studying dextromethorphan, a common ingredient in cough medicine. It's safe at regular doses, but higher amounts can cause problems like dizziness, confusion, or even hallucinations. Most side effects occur with large doses or when combined with other substances.

Researchers are excited about these treatments because they offer a novel approach to tackling emotional numbness, a condition often managed with antidepressants or therapy. Unlike the standard options, which typically take weeks to show results, psilocybin and dextromethorphan potentially provide rapid relief through their unique mechanisms. Psilocybin, a psychedelic compound, targets serotonin receptors in the brain, possibly leading to increased emotional connectivity and awareness. Dextromethorphan, usually found in cough medicine, acts on the brain's NMDA receptors, offering a different pathway to potentially lift emotional numbness. These innovative approaches may pave the way for faster, more effective relief for those struggling with this condition.

Research has shown that psilocybin, one of the treatments in this trial, can significantly improve anxiety and depression symptoms over time. Some patients experience faster relief compared to traditional treatments. In one study, 57% of patients undergoing psilocybin-assisted therapy saw their symptoms disappear, a higher rate than those using other treatments. Psilocybin has also been compared to the antidepressant escitalopram and demonstrated similar effectiveness in improving mood over six months.